Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
However, all integrase inhibitors were associated with similar weight gain.
The Department of Health and Human Services has updated its HIV treatment and prevention guidelines for pregnant people and their infants.
Compared with efavirenz-based regimens, dolutegravir-containing ones resulted in fewer switches and better viral control.
The São Paulo Patient is no longer HIV-free after more than 15 months off treatment, but was it a relapse or reinfection?
A 30-year retrospective review of abnormalities among infants born to women using antiretrovirals shows low, consistent levels.
Study results confirm that dolutegravir is a safe and effective treatment for pregnant women with HIV.
The findings highlight an ongoing need for better integration of HIV care with sexual and reproductive health care.
PrEPception, breast feeding and HIV trial participation are front and center in updated federal guidelines.
Globally, a child contracts HIV every 100 seconds. A new, affordable treatment is available, but the COVID-19 pandemic hinders access.
This finding among sub-Saharan Africans is quite concerning since dolutegravir is now the preferred first-line HIV treatment worldwide.
This may reflect loss of the weight-suppressing effect of the older version of the drug.
More studies link dolutegravir and other drugs to weight gain among people with HIV.
The effect is greater for women, and it could have a detrimental effect on pregnancy outcomes at the population level.
Previously, kids weighing 44 to 88 pounds had to take lower doses—which are less available worldwide—and do so more than once a day.
A 2018 report had suggested that HIV-positive women’s use of the drug at conception increased the risk of the rare birth defects.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.